Amedisys Inc (AMED) Receives Average Rating of “Buy” from Brokerages

Amedisys Inc (NASDAQ:AMED) has earned a consensus rating of “Buy” from the fifteen research firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $79.20.

A number of research firms have recently weighed in on AMED. ValuEngine raised Amedisys from a “hold” rating to a “buy” rating in a report on Tuesday, May 8th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research report on Wednesday, May 9th. Craig Hallum lifted their price objective on Amedisys from $60.00 to $82.00 and gave the company a “buy” rating in a research report on Wednesday, May 9th. TheStreet raised Amedisys from a “c+” rating to an “a-” rating in a research report on Monday, May 7th. Finally, Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 3rd.

In other Amedisys news, Director Jake L. Netterville sold 4,096 shares of the business’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $80.44, for a total transaction of $329,482.24. Following the completion of the sale, the director now owns 77,660 shares of the company’s stock, valued at $6,246,970.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David B. Pearce sold 398 shares of the business’s stock in a transaction dated Wednesday, July 25th. The shares were sold at an average price of $94.18, for a total value of $37,483.64. Following the sale, the insider now directly owns 12,216 shares of the company’s stock, valued at approximately $1,150,502.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,457,201 shares of company stock valued at $181,841,460. Company insiders own 2.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Itau Unibanco Holding S.A. purchased a new stake in Amedisys during the second quarter valued at about $149,000. SG Americas Securities LLC purchased a new stake in Amedisys during the first quarter valued at about $123,000. Moneta Group Investment Advisors LLC purchased a new stake in Amedisys during the second quarter valued at about $181,000. Cubist Systematic Strategies LLC grew its position in Amedisys by 1,086.0% during the second quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after acquiring an additional 2,172 shares during the period. Finally, Mount Yale Investment Advisors LLC purchased a new stake in Amedisys during the first quarter valued at about $151,000. 93.35% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ AMED traded up $0.01 during trading on Wednesday, reaching $124.50. The company had a trading volume of 5,357 shares, compared to its average volume of 447,402. Amedisys has a twelve month low of $45.60 and a twelve month high of $125.10. The stock has a market cap of $3.96 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.96 and a beta of 0.61. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The company had revenue of $411.60 million during the quarter, compared to analysts’ expectations of $403.62 million. During the same period in the previous year, the firm posted $0.62 earnings per share. analysts anticipate that Amedisys will post 3.42 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Read More: Analyst Ratings

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply